VFMCRP announces U.S. Court upholds validity of Velphoro® patent
14.9.2022 16:05:00 EEST | Business Wire | Press release
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRP’s favor regarding U.S. patent no. 9,561,251 which covers the formulation for Velphoro® (sucroferric oxyhydroxide). The decision, subject to appeal, holds that the generic sucroferric oxyhydroxide product proposed by Teva Pharmaceuticals USA, Inc., in its Abbreviated New Drug Application (ANDA) will infringe the Velphoro® U.S. patent no. 9,561,251, which expires in July 2030 (including pediatric extension). Currently, Velphoro® is protected by multiple Orange Book listed patents which expire between May 2029 and May 2035.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220821005007/en/
A further ANDA patent infringement lawsuit against Teva based on patents no. 10,682,376, no. 10,695,367 and no 11,013,761, all expiring in May 2029 remains pending.
“CSL Vifor welcomes the decision by the U.S. District Court to uphold the patent validity of Velphoro® which highlights the innovation and strength of our intellectual property,” said Florian Jehle, Chief Executive Officer of VFMCRP. “We are vigorously defending our intellectual property and protecting our market position. With this decision, we can continue to deliver this innovative drug to improve the lives of patients with chronic kidney disease on dialysis.”
VFMCRP has previously settled disputes with Lupin Pharmaceuticals, Inc and Annora Pharma Pvt. Ltd. which had filed ANDAs to market a generic version of Velphoro®. These ANDA filers will be able to launch a generic version of Velphoro® in the United States on an agreed-upon date. Details of all settlements are confidential.
About CSL Vifor
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).
The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com.
About Velphoro®
Velphoro® is a non-calcium, iron-based, chewable phosphate binder approved for the control of phosphate levels in the blood of adults with chronic kidney disease on dialysis. Velphoro® has been launched in 32 countries at the end of 2021, with more than 100,000 patients estimated to use the drug on a yearly basis.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220821005007/en/
Contact information
CSL Vifor Media Contact
Thomas Hutter
Mobile: +41 79 957 96 73
Email: media@viforpharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Armis Announces Armis Centrix™ for Vulnerability Management Detection and Response to Reduce Cyber Risk and Eliminate Operational Friction10.3.2026 14:00:00 EET | Press release
Armis, the cyber exposure management & security company, today announced Armis Centrix™ for Vulnerability Management Detection and Response. The solution enables security teams to precisely identify and validate vulnerabilities across all of an organization’s assets in real time. Armis’ unified approach to vulnerability assessment results in greater accuracy, faster detection time and reduced operational costs. "Waiting weeks for a vulnerability scan that still misses essential assets is no longer sufficient to combat AI-powered cyberattacks,” said Nadir Izrael, CTO and Co-Founder at Armis. “Organizations need a continuous view of their complete environment to stay ahead of threats. Armis' new solution delivers more accurate, targeted results than traditional vulnerability management solutions with a fraction of the scans. It empowers security teams to shift from a reactive approach that relies on stale data to targeted, real-time vulnerability detection, allowing them to save time, en
Wolters Kluwer Releases 2026 Future Ready Lawyer Survey Report, Highlighting Rapid AI Gains and Shifting Power Dynamics10.3.2026 14:00:00 EET | Press release
Wolters Kluwer Legal & Regulatory has published the results of its global 2026 Future Ready Lawyer Survey, the preeminent source of insights from lawyers in law firms and corporate legal departments across the U.S., China and nine European countries. The findings show an industry coming to grips with the accelerated adoption of AI technology, an ambitious undertaking that has yielded long sought-after efficiencies across workflows and business practices, while raising unexpected challenges to ethics and infrastructure. “The Future Ready Lawyer global report has always reflected an industry in motion,” said Martin O'Malley, CEO of Wolters Kluwer Legal & Regulatory. “What’s most striking this year is how rapidly legal professionals are accelerating to meet that change by reshaping business models, rethinking long‑held dynamics, and embracing new ways to deliver value through both evolving skills and bold technology.” AI Delivers, Challenges Persist A substantial majority of respondents (
Nexpring Health Invests in May Health to Advance a Novel Technology to Treat PCOS-Related Infertility10.3.2026 14:00:00 EET | Press release
Nexpring Health, a global leader in assisted reproductive technology (ART) solutions, today announced a strategic investment in May Health, a medical device company pioneering a novel treatment approach for women with polycystic ovary syndrome (PCOS)-related infertility. Nexpring Health joined May Health’s €10 million ($11.7M) financing round alongside investors including Sofinnova Partners, Trill Impact, and Bpifrance. This investment reflects Nexpring Health's commitment to driving meaningful innovation that moves the field of fertility care forward and goes beyond the products in the lab by supporting the innovations that redefine what’s possible for patients and the clinicians who serve them. Backing the Breakthrough That PCOS Patients Need PCOS is the most common endocrine condition among reproductive-aged women and a leading cause of female infertility, affecting an estimated 10–13% of women worldwide. 1,2 Women with PCOS-related infertility often struggle to become pregnant beca
United UATP, Powered by TreviPay, Expands Corporate Travel Billing Program to New Global Markets10.3.2026 14:00:00 EET | Press release
UATP, the global network that enables organizations to simplify payment processes and expand their payment capabilities, today announced the expansion of United Airlines’ cost-free UATP billing program (“United UATP”), powered by TreviPay, to Europe, Australia and New Zealand. This expansion opens new opportunities for corporate customers and travel agencies in these regions to access the benefits of United UATP, including cost-free, streamlined travel expense reconciliation. Since 2015, United UATP has collaborated with TreviPay, a fully managed B2B payments platform, to power its streamlined solution for air travel payments in the U.S. and Canada. For companies currently benefitting from the United UATP billing program, TreviPay handles customer service, underwriting risk, and manages the processing, invoicing in local currencies, and accounts receivable automation, including disputes, collections and reconciliation. A consolidated invoice process provides streamlined access to Level
Perion's AI Agent Outmax Now Available for TikTok, Delivering Up to 25% Greater Media Performance in Early Results10.3.2026 13:00:00 EET | Press release
Perion Network Ltd. (NASDAQ and TASE: PERI), an advanced technology leader solving for the complexities of digital advertising through AI-native execution infrastructure, today announced the launch of its proprietary Outmax AI agent for TikTok. This integration extends Perion’s capabilities to one of the fastest-growing global advertising platforms, with nearly 1.6 billion users worldwide and rapidly expanding advertiser adoption as brands increasingly prioritize TikTok in their media strategies. TikTok’s advertising revenue is expected to exceed $50 billion by 20271. Perion’s Outmax AI agent is embedded within Perion’s AI-native infrastructure, designed to increase advertiser efficiency and performance. Fully integrated with TikTok, Outmax applies algorithmic intelligence beyond native platform defaults, enabling advertisers to optimize against brand-defined business outcomes rather than platform-standard KPIs. The new Outmax for TikTok AI Model is already delivering up to 25% better
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom